Search

Protagonist Therapeutics Inc

Closed

SectorHealthcare

151.35 -0.39

Overview

Share price change

24h

Current

Min

148

Max

152.63

Key metrics

By Trading Economics

Income

159M

163M

Sales

157M

213M

P/E

Sector Avg

140.187

57.002

EPS

2.29

Profit margin

76.285

Employees

141

EBITDA

162M

165M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+10.46% upside

Dividends

By Acuity

Next Earnings

4 lis 2026

Market Stats

By TradingEconomics

Market Cap

1.2B

9.7B

Previous open

151.74

Previous close

151.35

News Sentiment

By Acuity

34%

66%

92 / 340 Ranking in Healthcare

Protagonist Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

12 sie 2026, 23:31 UTC

Social Media

Protagonist Therapeutics Inc gains after-market, reaching a high above Wednesday's close. Investor interest grows amid social media discussions on increasing positions.

11 sie 2026, 23:01 UTC

Protagonist Therapeutics Inc shares are higher in after-market hours, though no specific news explains the movement amid earlier volatility and fluctuations.

10 sie 2026, 23:46 UTC

Protagonist Therapeutics Inc shares are higher in after-market hours, with notable strength above the 20-day moving average and near the upper end of its one-month range.

6 sie 2026, 19:52 UTC

Social Media
News

Protagonist Therapeutics shares rise following multiple price target upgrades, including Citi's increase to $175, amid positive sentiment on drug approvals and pharmacokinetic data.

5 sie 2026, 22:02 UTC

News

Protagonist Therapeutics reports Q2 net income of $162.8 million, up from a loss last year. Shares are higher in after-market trading following the results.

4 sie 2026, 21:03 UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, supported by their position above the 20-day moving average. No specific news was identified.

3 sie 2026, 19:36 UTC

Protagonist Therapeutics Inc shares are lower today, continuing a decline since Friday. The stock is near the lower end of its one-month range.

31 lip 2026, 19:36 UTC

Correlated Moves

Protagonist Therapeutics Inc is lower today amid broader weakness in the Biotechnology sector. Earlier in the session, shares pulled back from a high.

30 lip 2026, 21:02 UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, amid notable volatility and significant price swings since Thursday's close.

29 lip 2026, 19:43 UTC

Macro Event

Protagonist Therapeutics Inc shares are lower amid market volatility following the Federal Reserve's decision to maintain interest rates, reflecting broader uncertainty.

28 lip 2026, 21:01 UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, maintaining a notable gain since Tuesday's close, despite no specific news identified.

27 lip 2026, 20:02 UTC

Social Media

Protagonist Therapeutics shares are lower despite Jefferies raising its price target to $171 and Cowen increasing its peak royalty revenue forecast to $1.4 billion.

22 lip 2026, 19:42 UTC

News

Protagonist Therapeutics Inc is trading lower today, continuing a decline since Tuesday amid rising crude oil prices and market tensions related to Iran.

21 lip 2026, 19:06 UTC

Protagonist Therapeutics Inc shares are higher today, continuing an upward trend since Monday's close, supported by gains in the semiconductor sector.

20 lip 2026, 19:41 UTC

News
Social Media

Protagonist Therapeutics shares are lower as analysts raise price targets and revenue forecasts ahead of Q2 earnings, despite a noted 0% probability of success for PN-881.

Peer Comparison

Price change

Protagonist Therapeutics Inc Forecast

Price Target

By TipRanks

10.46% upside

12 Months Forecast

Average 163.8 USD  10.46%

High 186 USD

Low 121 USD

Based on 10 Wall Street analysts offering 12 month price targets forProtagonist Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

10

Buy

0

Hold

0

Sell

Sentiment

By Acuity

92 / 340 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
help-icon Live chat